Silexion Therapeutics (SLXN) Price & Analysis

Compare

197 Followers

SLXN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.37 - $121.52

Previous CloseN/A

Volume52.80K

Average Volume (3M)698.75K

Market Cap

$7.58M

Enterprise Value$7.25M

Total Cash (Recent Filing)$3.47M

Total Debt (Recent Filing)$3.70M

Price to Earnings (P/E)―

Beta-0.08

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-19.98

Shares Outstanding2,123,892

10 Day Avg. Volume2,048,108

30 Day Avg. Volume698,754

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.96

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-249.94

Enterprise Value/Ebitda-0.40

Forecast

1Y Price Target

$24.00

Price Target Upside564.82% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentSilexion announced additional preclinical data for SIL-204 finding systemic subcutaneous administration reaches organs where pancreatic cancer metastasizes and generates anti-tumor activity.

Market OpportunitySilexion found antitumor activity in KRAS-mutated lung cancer cells, further validating SIL-204’s potential across multiple cancer types, which could increase the market opportunity for SIL-204 and Silexion.

Bears Say

Financial ConcernsThe 12-month price target was reduced to $24.00 due to dilution from the recent capital raise and potential additional dilution for future raises to fund the clinical study.

Silexion Therapeutics News

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Investors looking for all of the latest stock market stories on Thursday will want to check out the...

9d ago

AMD

Silexion Therapeutics prices 1.5M shares at $4.00 in public offering

Silexion Therapeutics (SLXN) announced the pricing of a public offering of an aggregate of 1,500,000 of the Company’s...

9d ago

SLXN

Why Is Silexion Therapeutics Stock (SLXN) Up 190% Today?

Silexion Therapeutics stock was up on Thursday after the company posted positive pre-clinical data. ...

9d ago

SLXN

Silexion Therapeutics announces preclinical data on SIL204

Silexion Therapeutics (SLXN) announced new preclinical data demonstrating that subcutaneously administered SIL204 successfully reaches all primary sites of...

9d ago

SLXN

Silexion Therapeutics selects AMS as CRO for SIL204 Phase 2/3 trials

Silexion Therapeutics (SLXN) selected a contract research organization to support its upcoming Phase 2/3 clinical trials for SIL204,...

16d ago

SLXN

Silexion Therapeutics Converts Debt to Equity for Nasdaq Compliance

Silexion Therapeutics ( ($SLXN) ) has shared an update. On September 15, 2025, Silexion Therapeutics Corp issued 450,000...

5d ago

SLXN

Silexion Therapeutics Announces $6M Public Offering

Silexion Therapeutics ( ($SLXN) ) just unveiled an announcement. On September 11, 2025, Silexion Therapeutics announced the pricing...

8d ago

SLXN

Silexion Therapeutics Reveals Positive Preclinical Data for SIL204

Silexion Therapeutics ( ($SLXN) ) has issued an announcement. On September 11, 2025, Silexion Therapeutics announced positive preclinical...

9d ago

SLXN

Silexion Therapeutics Partners with AMS for Clinical Trials

Silexion Therapeutics ( ($SLXN) ) has issued an update. On September 4, 2025, Silexion Therapeutics announced the selection...

16d ago

SLXN

Silexion Therapeutics Unveils New Oncogene Therapy Updates

An announcement from Silexion Therapeutics ( ($SLXN) ) is now available. On September 2, 2025, Silexion Therapeutics announced...

18d ago

SLXN

Silexion Therapeutics Executes Reverse Stock Split

Silexion Therapeutics ( ($SLXN) ) has shared an announcement. On July 28, 2025, Silexion Therapeutics Corp implemented a...

1M ago

SLXN

Silexion Therapeutics Increases Authorized Share Capital

Silexion Therapeutics ( ($SLXN) ) has provided an announcement. At the extraordinary general meeting of Silexion Therapeutics Corp,...

1M ago

SLXN

Silexion Therapeutics reports Q2 EPS ($4.32) vs. ($197.80) last year

Ilan Hadar, Chairman and CEO of Silexion commented: “The second quarter of 2025 marked a transformative period for...

1M ago

SLXN

Buy Rating for Silexion Therapeutics Driven by Promising Preclinical Data and Financial Strength

Maxim Group analyst Naz Rahman reiterated a Buy rating on Silexion Therapeutics yesterday and set a price target...

2M ago

SLXN

SLXN FAQ

What was Silexion Therapeutics’s price range in the past 12 months?

Silexion Therapeutics lowest stock price was $3.37 and its highest was $121.52 in the past 12 months.

What is Silexion Therapeutics’s market cap?

Silexion Therapeutics’s market cap is $7.58M.

When is Silexion Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Silexion Therapeutics’s earnings last quarter?

Silexion Therapeutics released its earnings results on May 13, 2025. The company reported -$3.9 earnings per share for the quarter, missing the consensus estimate of -$3.3 by -$0.6.

Is Silexion Therapeutics overvalued?

According to Wall Street analysts Silexion Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Silexion Therapeutics pay dividends?

Silexion Therapeutics does not currently pay dividends.

What is Silexion Therapeutics’s EPS estimate?

Silexion Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Silexion Therapeutics have?

Silexion Therapeutics has 2,123,892 shares outstanding.

What happened to Silexion Therapeutics’s price movement after its last earnings report?

Silexion Therapeutics reported an EPS of -$3.9 in its last earnings report, missing expectations of -$3.3. Following the earnings report the stock price went down -4.605%.

Which hedge fund is a major shareholder of Silexion Therapeutics?

Currently, no hedge funds are holding shares in SLXN

Silexion Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-1342.57%

Trailing 12-Months

Asset Growth

-2.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Silexion Therapeutics (SLXN) Earnings & Revenues

Historic Earnings Reports

SLXN Stock 12 Month Forecast

Average Price Target

$24.00

▲(564.82% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","793":"$793","1580":"$1,580","399.5":"$399.5","1186.5":"$1,186.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,399.5,793,1186.5,1580],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.21,8.50153846153846,9.793076923076923,11.084615384615384,12.376153846153846,13.667692307692308,14.959230769230768,16.25076923076923,17.54230769230769,18.833846153846153,20.125384615384615,21.416923076923077,22.70846153846154,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.21,8.50153846153846,9.793076923076923,11.084615384615384,12.376153846153846,13.667692307692308,14.959230769230768,16.25076923076923,17.54230769230769,18.833846153846153,20.125384615384615,21.416923076923077,22.70846153846154,{"y":24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.21,8.50153846153846,9.793076923076923,11.084615384615384,12.376153846153846,13.667692307692308,14.959230769230768,16.25076923076923,17.54230769230769,18.833846153846153,20.125384615384615,21.416923076923077,22.70846153846154,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1528.2,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1579.5,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":197.1,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":75.09,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.67,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.05,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >